Xuan Gu Bao·2025-12-17 11:58Group 1: Resumption of Trading - Dongxing Securities and Xinda Securities have approved the merger with CICC, leading to the resumption of their stocks [1] - CICC plans to conduct a share swap merger with Dongxing Securities and Xinda Securities at a swap price of 36.91 yuan per share, resulting in stock resumption [1] - Meike Home intends to acquire control of Wande, leading to a suspension of its stock [1] - Fenglong Co., Ltd. is planning a change in control, resulting in a suspension of its stock [1] Group 2: Capital Increase and Mergers - Shenzhen Urban Transport is planning a capital increase of 1.8 billion yuan for the development of intelligent transportation models and global business expansion [2] - Tongye Technology intends to purchase 100% of Silin Technology's shares in cash, focusing on communication chip design [2] - Shengxing Co., Ltd. plans to raise no more than 1.157 billion yuan for new production bases in Vietnam and Sichuan [2] Group 3: Share Buybacks and Equity Transfers - China Metallurgical Group plans to repurchase shares worth between 1 billion and 2 billion yuan [3] - Jiayuan Technology's shareholders plan to transfer 3.24 million shares, accounting for 2.51% of the total share capital [4] - Jintian Titanium Industry is transferring 4.9% of its shares through an inquiry by the National Industrial Investment Fund [5] Group 4: External Investments and Daily Operations - Kangtai Biological has received clinical trial approval for its hepatitis B vaccine [6] - Zhifei Biological's application for a clinical trial of a modified smallpox vaccine has been accepted [7] - Hongbo New Materials' subsidiary is set to sign a technology licensing and business transfer agreement with the U.S. for a total price of 377 million yuan [7] - China CRRC has signed contracts totaling 53.31 billion yuan, including 16.65 billion yuan for wind power and energy storage equipment [8] - Xiechuang Data plans to invest in the development and production of optical chips and modules in Guangzhou [8] - Tongrentang clarified that it does not hold any equity or investment rights in Sichuan Health Pharmaceutical related to the reported Antarctic krill oil [9]